Clinical pharmacology of human insulin of recombinant DNA origin in healthy volunteers. 1982

A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui

The serum insulin, fractional absorption, serum human C-peptide, and plasma glucose responses of normal fasting subjects were compared after the subcutaneous and intravenous administration of human insulin (recombinant DNA) and Novo Actrapid insulin. While no statistical difference at each time point was observed between the two insulins, for each time point after 0.05 and 0.1 U/kg s.c., the 0-6 h area under curve (AUC) after the 0.05 U/kg dose was greater for human insulin than for pork insulin. There was no difference in the 0-6 h AUC after the 0.1 U/kg s.c. dose. The serum human C-peptide responses to the two insulins were virtually identical. With the 0.05 U/kg s.c. dose, hypoglycemic effect of human insulin was greater than for Actrapid. This difference did not occur after 0.1 U/kg s.c. Following intravenous administration using 0.05 U/kg, the serum IRI, serum C-peptide, and glucose responses were the same. These data indicate only slight differences between human insulin and Actrapid insulin.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
January 1982, Diabetes care,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
September 1993, Journal of cardiovascular pharmacology,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
June 1983, Diabetes,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
January 1982, Diabetes care,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
January 1982, Diabetes care,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
January 1982, Diabetes care,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
December 1991, Clinical pharmacology and therapeutics,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
December 1993, Diabetes care,
A Ebihara, and K Kondo, and K Ohashi, and K Kosaka, and T Kuzuya, and S Tarui
August 1997, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!